Jazayeri Seyedeh Ferdows, Ghods Roshanak, Hashem Dabaghian Fataneh, Shojaii Asie, Moravej Seyed Ali Al-Hadi, Khadem Ebrahim, Seyedian Seyed Saeed
Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran.
Department of Persian Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran.
Evid Based Complement Alternat Med. 2021 Mar 27;2021:6693887. doi: 10.1155/2021/6693887. eCollection 2021.
This study aims to evaluate the effects of () seed on liver enzymes and ultrasound patterns in nonalcoholic fatty liver disease (NAFLD).
In this randomized double-blind placebo-controlled clinical trial, 74 patients with NAFLD were administered either 2 g or placebo twice daily for 12 weeks. All patients were advised to follow the recommendations for daily exercise and diet modification. Levels of liver enzymes as well as other laboratory indexes were measured at the beginning of the study and after 12 weeks. Indeed, the alteration in ultrasound grade was evaluated in NAFLD patients.
Sixty-three participants completed the study in the intervention and control groups. The mean age of participants was 43.3 (±8.927) and 38.7 (±8.48) years in the intervention and control groups, respectively. group showed significant reduction in alanine aminotransferase (ALT) (47.32 ± 21.77 IU/L vs. 50.03 ± 21.19, = 0.021), aspartate aminotransferase (AST) (28.29 ± 10.49 IU/L vs. 32.03 ± 13.30, = 0.004), triglyceride (TG) (200.93 ± 106.741 mg/dl vs. 183.75 ± 73.96, = 0.001), waist circumference (WC) (101.25 ± 9.27 cm vs. 101.18 ± 8.63, = 0.027), and grade of fatty liver in ultrasonography ( = 0.038), comparing to the placebo group. There was no significant difference between the two groups regarding serum levels of fasting blood sugar (FBS), high-density lipoprotein (HDL), low-density lipoprotein (LDL), cholesterol, and other outcomes.
supplementation with a daily dose of 2 g for 12 weeks improved serum levels of ALT, AST, and TG in patients with NAFLD. Further studies with a larger sample size are recommended.
本研究旨在评估（）种子对非酒精性脂肪性肝病（NAFLD）患者肝酶及超声图像的影响。
在这项随机双盲安慰剂对照临床试验中，74例NAFLD患者被给予每日两次2克（）或安慰剂，持续12周。所有患者均被建议遵循日常锻炼和饮食调整建议。在研究开始时及12周后测量肝酶水平及其他实验室指标。实际上，对NAFLD患者的超声分级变化进行了评估。
干预组和对照组中有63名参与者完成了研究。干预组和对照组参与者的平均年龄分别为43.3（±8.927）岁和38.7（±8.48）岁。与安慰剂组相比，（）组的丙氨酸氨基转移酶（ALT）（47.32±21.77 IU/L对50.03±21.19，P = 0.021）、天冬氨酸氨基转移酶（AST）（28.29±10.49 IU/L对32.03±13.30，P = 0.004）、甘油三酯（TG）（200.93±106.741 mg/dl对183.75±73.96，P = 0.001）、腰围（WC）（101.25±9.27 cm对101.18±8.63，P = 0.027）以及超声检查中的脂肪肝分级（P = 0.038）均有显著降低。两组在空腹血糖（FBS）、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）、胆固醇及其他指标的血清水平方面无显著差异。
NAFLD患者每日补充2克（），持续12周，可改善血清ALT、AST和TG水平。建议进行更大样本量的进一步研究。
